"It is not as though approval of follow-on biologics will be a huge paradigm shift," said Amgen Vice President David Beier. "Mainly because there are frequently already second generation versions of biological products on the market that offer superior patient value in terms of safety, convenience and efficacy."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.